

Laduviglusib, GMP Grade

Cat. No. Laduviglusib-05 **Lot. No.** (See product label)

SPECIFICATION

Product Overview	Laduviglusib (CHIR-99021) (GMP) is Laduviglusib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture.
Description	Laduviglusib is a potent, orally active and selective GSK-3 α / β inhibitor.
Form	Solid, White to off-white
Target	GSK-3; Wnt; β -catenin; Autophagy
In Vitro	Laduviglusib (GMP) (20 μM, 21 days) transdifferentiates mouse fibroblasts to neurons (determined by increased number of TAUEGFP-/TUJ1-positive neuronal cells). Laduviglusib (GMP) (3-5 μM, 2 days) induces somatic cells differentiation of pluripotent stem (PS) cells (the detailed method refers to the reference). Laduviglusib (GMP) (12 μM, 5 days) converts human fibroblasts (HFF) into functional cardiomyocytes. Laduviglusib (GMP) (3 μM, 4 days, hESCs) activates the canonical WNT signaling pathway, confirmed by β-catenin translocation into the nucleus. Laduviglusib (GMP) (in MEFs expressing MyoD) enhances the marked increase in the number of proliferative cells led by RepSox (GMP) together with Forskolin. Laduviglusib (GMP) (5 μM, 1 day) can be used to generate islets (hCiPSC-islets) from human chemically induced pluripotent stem cells (hCiPSC).
IC50 & Target	GSK-3 β : 6.7 nM (IC50) GSK-3 α : 10 nM (IC50) CDC2: 8800 nM (IC50)

 Tel: 1-631-559-9269 1-516-512-3133

 Email: info@creative-biomart.com  Fax: 1-631-938-8127

 45-1 Ramsey Road, Shirley, NY 11967, USA

CAS	252917-06-9
Formula	C ₂₂ H ₁₈ Cl ₂ N ₈
Molecular Mass	465.34
Shipping	Shipping with dry ice.
GENE INFORMATION	
Pathway	PI3K/Akt/mTOR; Stem Cell/Wnt; Autophagy
Synonyms	Laduviglusib; CHIR-99021; CT99021

 Tel: 1-631-559-9269 1-516-512-3133

 Email: info@creative-biomart.com  Fax: 1-631-938-8127

 45-1 Ramsey Road, Shirley, NY 11967, USA